Endo And Teva Are First With US Everolimus
Endo’s Par Announces Immediate Launch
Patent litigation settlements have paved the way for Endo’s Par and Teva to secure the first US approvals for generic versions of Novartis’ Afinitor everolimus brand.
You may also be interested in...
Endo has named a head for its sterile injectables and generics operations; Hikma has appointed an R&D head; Acino has a new leader for its Latin American business; Alvogen has appointed a general counsel; and Julphar has shaken up its senior management team.
While a Delaware district court incorrectly held Hikma’s West-Ward to a heightened standard on motivation to combine prior art, that error did not prove fatal to its decision to uphold the validity of a US patent protecting Novartis’s Afinitor everolimus treatment for RCC until May 2026.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.